timothy sykes logo
enGene Stock Plunges As LEGEND Trial Downgrades Mount Thumbnail
G Google News

enGene Stock Plunges As LEGEND Trial Downgrades Mount

BRYCE TUOHEY•UPDATED MAY. 9, 2026, 10:06 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

enGene Therapeutics Inc.’s stocks have been trading down by -12.79 percent amid heightened concern over its latest clinical trial outlook.

Candlestick Chart

Weekly Update May 04 – May 08, 2026: On Saturday, May 09, 2026 enGene Therapeutics Inc. stock [NASDAQ: ENGN] is trending down by -12.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

enGene (ENGN) is a clinical‑stage gene therapy company with no revenue, deeply negative profitability (ROE ~‑46%, ROA ~‑39%), and heavy R&D spend (~$22.3M in the quarter vs. zero sales). Cash and short‑term investments are sizable at ~$276M, with excellent liquidity (current ratio 11.8x, debt/equity 0.12x) and working capital of ~$265M, implying >2 years of runway at current burn (~$29M operating cash outflow this quarter). Valuation is asset‑support driven (P/B ~0.4x; EV negative), reflecting severe skepticism on the pipeline.

The stock’s technical profile is broken. After trading near $8, ENGN collapsed intraday to the low $1s, printing a massive gap‑down and closing the week around $1.50 with extremely elevated volume versus historical norms, confirming institutional distribution and a new bearish regime. The dominant trend is sharply down with no credible base. The first meaningful technical level is resistance at ~$2.00 (gap‑fill/overhead supply); risk‑tolerant traders can short against $2 with a $1.20 support/stop zone.

ENGN now trades as a binary, data‑driven special situation with unfavorable risk‑reward versus biotech benchmarks (XBI) and broader Healthcare indices (XLV). Multiple downgrades (Guggenheim, Piper, Leerink, Oppenheimer, Raymond James, Citizens) and aggressive target cuts (e.g., $19→$2) underscore a structurally weaker LEGEND profile in an increasingly crowded NMIBC market, while a shareholder‑rights investigation adds headline and litigation risk. Relative to peers, ENGN warrants an underweight stance with a 6–12 month trading range of $1–2 and capped upside near $3 absent unexpectedly strong data.

Quick Financial Overview

The price action in ENGN tells you how violent the sentiment shift has been. After trading near $7.96 to $8.85 earlier in the week, the stock collapsed to the $1.72–$1.88 range and then slid again to around $1.50. That is an extreme repricing in a few sessions, consistent with traders reacting to a major negative data surprise and a wall of analyst downgrades around the LEGEND trial. Intraday, a 5-minute candle showing a drop from the $1.70s to a $1.45 low before settling near $1.50 highlights heavy selling pressure and weak bids.

Fundamentally, enGene Therapeutics Inc. remains a pre-commercial, cash-burning biotech. Recent quarterly numbers show net income of about -$29.8M and operating cash flow near -$28.9M, which is typical for a clinical-stage name but still matters for runway. The balance sheet lists roughly $275.9M in cash and short-term investments and working capital above $260M, giving ENGN a sizable cushion to fund operations despite the setback.

More Breaking News

Key ratios confirm the early-stage risk profile. Returns on equity and assets are deeply negative, while the price-to-book ratio near 0.41 implies the stock now trades at a steep discount to its book value of about $4.20 per share. Leverage is modest, with total debt to equity near 0.12 and a strong current ratio around 11.8, which helps reduce near-term liquidity risk. For traders, the story is not about profits today but about whether the LEGEND program can still justify any recovery from these compressed levels.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading ENGN

Millionaire's
POV on ENGN

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”